| Project/Area Number |
17590671
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Gastroenterology
|
|---|
| Research Institution | Iwate Medical University |
|---|
Principal Investigator |
CHIBA Toshimi Iwate Medical University, School of Medicine, Lecturer (40254784)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
ORII Seishi Iwate Medical University, School of Medicine, Associate Professor (00158833)
SUGAI Tamotu Iwate Medical University, School of Medicine, Associate Professor (20187628)
|
|---|
| Project Period (FY) |
2005 – 2007
|
| Project Status |
Completed (Fiscal Year 2007)
|
| Budget Amount *help |
¥3,240,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥240,000)
Fiscal Year 2007: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2006: ¥800,000 (Direct Cost: ¥800,000)
Fiscal Year 2005: ¥1,400,000 (Direct Cost: ¥1,400,000)
|
|---|
| Keywords | irritable bowel syndrome / cholinergic receptor muscarinic 3 / B3-adrenoceptor / gene polymorphisms / 過敏性腸症侯群 |
|---|
| Research Abstract |
The association between polymorphisms in the cholinergic receptor muscarinic 3 (CHRM3) and β3-adrenoceptor (β3 AR) genes in irritable bowel syndrome (IBS) has been well established. We examined the association between the CHRM3 (rs3738435) and β_3 AR gene (Trp64Arg) polymorphisms. DNA was obtained from 82 IBS patients (32 diarrhea type, 45 constipation type, 5 unclassified) and 68 controls. Polymorphisms were determined by direct sequencing. No significant differences in CHRM3 polymorphisms were observed between IBS and controls. In contrast, β_3 AR (T/C + C/C) polymorphisms occurred at a significantly higher rate in IBS patients compared to controls (P<0.05). Furthermore, the rate of β_3 AR (T/C + C/C) polymorphisms in constipation-predominant IBS was significantly higher than that in diarrhea-predominant IBS. Thus, β_3 AR (Trp64Arg) polymorphisms appear to be strongly associated with IBS, particularly constipation-predominant IBS.
|
